Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Melanoma 7Leukemia, Myeloid, Acute 5Neoplasms 3Pathologic Complete Response 2Ovarian Neoplasms 2Myelodysplastic Syndromes 2Multiple Myeloma 2Fallopian Tube Neoplasms 2Wilms Tumor 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Smoldering Multiple Myeloma 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasm, Residual 1Mesothelioma, Malignant 1Leukemia 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Carcinoma 1Carcinogenesis 1Brain Neoplasms 1

Interventions

Cyclophosphamide 22blinatumomab 18Cytarabine 15fludarabine 13Azacitidine 12venetoclax 10fludarabine phosphate 10Rituximab 8Lenalidomide 7Dexamethasone 7Methotrexate 6Daunorubicin 6Mercaptopurine 5daratumumab 4Whole-Body Irradiation 4Vincristine 4Melphalan 4Idarubicin 4Etoposide 4Busulfan 4pembrolizumab 3obinutuzumab 3Radiotherapy 3Maintenance 3Immunotherapy, Adoptive 3Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Drug Therapy 3Cladribine 3Asparaginase 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasm, Residual × Monatide (IMS 3015) × Clear all
NCT05642195 2026-06-05

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Suspended
30 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡